Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
JNJ-7706621
CHF 0.00
In stock
SYN-1048-M0011 mgCHF 177.00
SYN-1048-M0055 mgCHF 298.00
SYN-1048-M01010 mgCHF 504.00
SYN-1048-M05050 mgCHF 1'185.00
SYN-1048-M100100 mgINQ
Product Details | |
---|---|
Synonyms | JNJ7706621 |
Product Type | Chemical |
Properties | |
Formula | C15H12F2N6O3S |
MW | 394.4 |
CAS | 443797-96-4 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: Aurora A - CDK7 - CDK5 - CDK4 - CDK2 | Kinase Group: Other | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | KDKUVYLMPJIGKA-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDK) and aurora kinases. It demonstrates highest potency on CDK1/2 with IC(50) values of 9nM and 4nM respectively. It shows more than 6-fold selectivity for CDK1/2 over CDK3/4/6.
Product References
- The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases: S. Emanuel, et al.; Cancer Res. 65, 9038 (2005)